Main menu

Vaccines

Vaccines

 

Pfizer has a rich history in vaccine research and development. Over the years, we’ve played a pivotal role in nearly eliminating the world of deadly diseases like smallpox and polio, and designing diverse vaccine delivery systems and technologies that have resulted in vaccines to prevent bacterial infections, like pneumococcal disease.

Our vaccine R&D program includes an ongoing focus on the prevention of pneumococcal disease, including in adults. We are also advancing vaccines for additional deadly adolescent and adult infections including Meningococcal B, Staphylococcus aureus and Clostridium difficile. We are leveraging leading technology in vaccine design and conjugation in an effort to provide preventative solutions to these complex, difficult-to-treat bacterial pathogens.

Pfizer is also exploring the power of novel therapeutic vaccines to provide long-lasting treatment benefits for chronic conditions and diseases such as smoking addiction and allergic asthma. Vaccines can generate high-levels of antibodies in the body that could prove beneficial for managing these difficult conditions.

Work with Us

If you’re interested in collaborating with us on vaccine development, visit our Vaccines Partnering page to learn more about the work we’re pursuing.

Vaccines Pipeline in Focus

Pipeline in Focus

We are currently conducting clinical trials with new vaccines designed to prevent deadly infections such as Meningococcal B, hospital-acquired Staphylococcus aureus infection and Clostridium difficile colitis. We are also advancing therapeutic vaccines for smoking cessation and allergic asthma.

Emilio Emini, Ph.D., Senior Vice President of Vaccine Research & Development at Pfizer, discusses the impact of vaccines and evolution of vaccine research.

Vaccine R&D

Pfizer’s Vaccine R&D

Pfizer is tackling deadly adult and adolescent infectious diseases, and evaluating therapeutic vaccines for chronic disease and conditions.